The Future of CRO Outsourcing Is Not Bigger Cost Savings. It's Smarter Integration.
The latest European Biotechnology Magazine September 2026 CRO/CDMO Special Issue highlights a fundamental shift in how biotech and pharma companies approach outsourcing: CRO selection is no longer primarily a cost decision. It is increasingly a capability decision. Sponsors are looking for specialized expertise, advanced technologies, and partners who can accelerate decision-making while reducing development risk. The emerging winning model is neither full integration nor pure specialization, but what the industry calls "intelligent integration."
A key challenge repeatedly identified across the industry is the growing risk of knowledge loss during handoffs between providers. Every transfer of process know-how, analytical methods, formulation data, or study history introduces complexity, delays, and potential risk.
At abc biopply, we believe this trend is particularly relevant for preclinical drug development.
As Europe's first fully integrated Organoid CRO, we have built our service model around the concept of Intelligent Integrated Preclinical Services:
✅ One study design and one project management team and no fragmented project handoffs
✅ Independent specialized platform, model and service providers partnering in a preclinical service network
✅ Fit-for-purpose model selection rather than technology-driven recommendations
✅ Seamless transition from 2D in vitro screening to validated 3D CoSeedis™ Humanized Multi-Organoid Models and, where required, synchronized in vivo studies
Our customers benefit from the expertise of dedicated specialists out of our preclinical competence network at every stage while receiving a fully coordinated program from a single source. This ensures that the right model is used for the right scientific question, whether that is traditional 2D assays, advanced 3D humanized multi-organoid systems, or complementary in vivo studies. Interested? Contact us service@biopply.com
A Call to Innovators, CROs, Technology Providers and Pharma Partners
The next generation of drug discovery will require stronger collaboration between specialized experts than ever before. We are always interested in addingselected strategic partnerships to our preclinical competence network that strengthens the preclinical ecosystem.Whether you are a pharmaceutical company, biotech innovator, CRO, technology provider, or if you offer complementary technologies, models, analytical capabilities or AI solutions, we invite you to explore how intelligent integration can accelerate the development programs of your customers. Contact us arne.faisst@biopply.com